Stockreport

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

Genenta Science S.p.A. - American Depositary Shares  (GNTA) 
PDF MILAN and NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased [Read more]